الخلاصة

Dopaminergic hypofunction have been involved in the pathogenesis of obesity and impaired glucose homeostasis. The aim of this study is to determine the effect of cabergoline on body weight, glycemic control and insulin resistance in pre-diabetic obese patients. This 12 week prospective control clinical study randomized 44 obese pre-diabetic patients into three groups. Group 1(N=13) the control, group 2 (N=16) received metformin 500mg-850mg BID and group 3 (N=15) received cabergoline 0.25-0.5mg twice weekly. The weight loss was not different among the three groups. Significant glycemic improvement started after 8 week of cabergoline while after 4 week of metformin treatment. At the end of study, cabergoline improved glycemic control and insulin resistance greater than control group. Metformin improved glycemic control greater than cabergoline while the change in insulin resistance was not significant between metformin and cabergoline. We can conclude that cabergoline improve glycemic control and insulin resistance in obese pre-diabetic patient